Oh Young Joo, Kim Jeong Yeon, Suh Jin Woong, Jeong Yujin, Choi Yumin, Lim Hyung-Jun, Sohn Jang Wook, Ahn Ki Hoon, Yoon Young Kyung
Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.
Institute of Emerging Infectious Diseases, Korea University, Seoul 02841, Republic of Korea.
J Clin Med. 2024 Dec 2;13(23):7327. doi: 10.3390/jcm13237327.
: The coronavirus disease 2019 (COVID-19) pandemic has significantly affected both supply and demand for blood transfusion. This study aimed to investigate the prescription patterns of blood products and identify the risk factors for blood transfusion in patients with severe COVID-19. : This nationwide population-based cohort study was performed in the Republic of Korea between January 2021 and December 2021. Adult patients (≥19 years) with severe COVID-19 who received oxygen therapy were examined. Data were obtained from the National Health Insurance Service database. : During the study period, 41,203 patients developed severe COVID-19. The overall transfusion rate was 7.11%, with 14,477 units of packed red blood cells, 4501 units of fresh frozen plasma, 20,532 units of platelet concentrates, and 1875 units of cryoprecipitate. Blood transfusion was independently associated with 90-day mortality (hazard ratio: 1.36, 95% confidence interval: 1.21-1.53, < 0.001). Multivariate logistic regression analysis identified underlying chronic kidney disease; exposure to surgery, thrombolysis, or thrombectomy; renal replacement therapy; mechanical ventilation; and extracorporeal membrane oxygenation as significant risk factors for blood transfusion in patients with severe COVID-19. Conversely, underlying cerebrovascular diseases, a Charlson Comorbidity Index score of ≥6, admission to intensive care units, and anticoagulant use were identified as protective factors. : This study provides an overview of blood transfusion patterns in patients with severe COVID-19. Understanding these patterns may help optimize the stockpiling of medical resources.
2019年冠状病毒病（COVID-19）大流行对输血的供需均产生了重大影响。本研究旨在调查血液制品的处方模式，并确定重症COVID-19患者输血的危险因素。：这项基于全国人群的队列研究于2021年1月至2021年12月在大韩民国进行。对接受氧疗的成年重症COVID-19患者（≥19岁）进行了检查。数据来自国民健康保险服务数据库。：在研究期间，41203名患者发展为重症COVID-19。总体输血率为7.11%，共输注浓缩红细胞14477单位、新鲜冰冻血浆4501单位、血小板浓缩物20532单位和冷沉淀1875单位。输血与90天死亡率独立相关（风险比：1.36，95%置信区间：1.21-1.53，<0.001）。多因素逻辑回归分析确定，潜在的慢性肾脏病；接受手术、溶栓或血栓切除术；肾脏替代治疗；机械通气；以及体外膜肺氧合是重症COVID-19患者输血的重要危险因素。相反，潜在的脑血管疾病、Charlson合并症指数评分≥6、入住重症监护病房和使用抗凝剂被确定为保护因素。：本研究概述了重症COVID-19患者的输血模式。了解这些模式可能有助于优化医疗资源的储备。
